Acquired Orphan Blood Disease Market Research Reveals Rapid Growth in Asia and Innovative Therapies
25 janv. 2024 05h39 HE
|
Research and Markets
Dublin, Jan. 25, 2024 (GLOBE NEWSWIRE) -- The "Acquired Orphan Blood Disease Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade,...
Myelodysplastic Syndrome Market to Register Stunning Growth, Estimates DelveInsight | Key Players in the Market - AbbVie, Gilead Sciences, Novartis, AstraZeneca, Sanofi, Incyte, Celgene, Fibrogen, Precigen
06 juin 2023 13h00 HE
|
DelveInsight Business Research LLP
New Year, USA, June 06, 2023 (GLOBE NEWSWIRE) -- Myelodysplastic Syndrome Market to Register Stunning Growth, Estimates DelveInsight | Key Players in the Market - AbbVie, Gilead Sciences, Novartis,...
Myelodysplastic Syndrome Treatment Market in U.S., Europe, and China to Surpass US$ 3,404.1 Million by 2027, Says Coherent Market Insights (CMI)
12 juil. 2021 08h40 HE
|
CMI
SEATTLE, July 12, 2021 (GLOBE NEWSWIRE) -- According to Coherent Market Insights, the U.S., Europe, and China Myelodysplastic Syndrome (MDS) Treatment market is estimated to be valued at US$ 2,042.6...
Bellicum Pharmaceuticals Reports First Quarter 2019 Financial Results and Provides Operational Update
07 mai 2019 07h30 HE
|
Bellicum Pharmaceuticals, Inc.
Interim data for BPX-601 accepted for presentation at upcoming American Society of Clinical Oncology (ASCO) Annual Meeting Rivo-cel™ on-track for topline data readout from BP-004 pediatric trial in...
FDA Approves Lixte Biotechnology’s IND to Conduct a Phase 1b/2 Trial of LB-100 in Patients with Myelodysplastic Syndrome at Moffitt Cancer Center
05 nov. 2018 13h00 HE
|
Lixte Biotechnology Holdings, Inc.
EAST SETAUKET, NY, Nov. 05, 2018 (GLOBE NEWSWIRE) -- Lixte Biotechnology Holdings, Inc. (OTCQB: LIXT) announced that the FDA approved its IND to conduct a Phase 1b/2 trial of the safety and...
Lixte Biotechnology Files an IND with the FDA to Conduct a Phase 1b/2 Trial of LB-100 in Patients with Myelodysplastic Syndrome at Moffitt Cancer Center
09 oct. 2018 09h45 HE
|
Lixte Biotechnology Holdings, Inc.
EAST SETAUKET, NY , Oct. 09, 2018 (GLOBE NEWSWIRE) -- Lixte Biotechnology Holdings, Inc. (OTCQB: LIXT) announced that it has submitted an IND to the FDA to conduct a Phase 1b/2 trial of the safety...
Lixte Biotechnology Announces a Clinical Trial Agreement with Moffitt Cancer Center to Initiate Phase 1b/2 Trial Evaluating the Safety and Efficacy of LB-100 in Treatment of Patients with Low or Intermediate-1 Risk Myelodysplastic Syndrome
21 août 2018 09h45 HE
|
Lixte Biotechnology Holdings, Inc.
EAST SETAUKET, NY, Aug. 21, 2018 (GLOBE NEWSWIRE) -- Lixte Biotechnology Holdings, Inc. (OTCQB: LIXT) announced that it has entered into a Clinical Trial Agreement and Exclusive License Agreement...
Actinium Pharmaceuticals Highlights Key Activities and Progress at BMT Tandem Meetings, the Combined Annual Meetings of the Two Leading Transplant Organizations
28 févr. 2018 07h30 HE
|
Actinium Pharmaceuticals
- Protocol changes to the control arm of the pivotal Phase 3 trial for Iomab-B well received at the Company’s investigator meeting and by Iomab-B’s scientific advisory board - Product theater...
Actinium Pharmaceuticals Appoints Dr. Dale L. Ludwig, Ph.D. as Chief Scientific Officer to Lead Efforts Focused on the Company’s AWE Technology Platform and Research Programs
08 janv. 2018 07h30 HE
|
Actinium Pharmaceuticals
- Dr. Ludwig brings over 20 years of leadership and management expertise from Eli Lilly and Company and Imclone Systems, Inc. in oncology antibody therapeutics discovery and development where he...
Actinium Pharmaceuticals Unveils Actimab-MDS and Planned Phase 2 Trial in Myelodysplastic Syndromes Targeted at Patients with High-Risk p53+ Genetic Mutations
05 déc. 2017 07h30 HE
|
Actinium Pharmaceuticals
Phase 2 clinical trial planned for 2018, Actimab-MDS intended to be a bridge to a bone marrow transplant, the only curative treatment option for patients with myelodysplastic syndromeTrial principal...